Richard S. Lindahl - Feb 8, 2023 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Signature
/s/ Jennifer Lynn Fox, Attorney-in-fact
Stock symbol
EBS
Transactions as of
Feb 8, 2023
Transactions value $
-$31,747
Form type
4
Date filed
2/10/2023, 07:35 PM
Previous filing
Mar 2, 2022
Next filing
Feb 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EBS Common Stock Award $0 +101 +0.47% $0.00 21.8K Feb 8, 2023 Direct F1
transaction EBS Common Stock Tax liability -$31.7K -2.4K -10.99% $13.25 19.4K Feb 8, 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2022 fiscal year, as certified by the Compensation Committee following the performance period. On February 08, 2023, the final certification date, the Compensation Committee certified the achievement of the 2020-2022 PSUs at a payout factor of 101.67% of target resulting in the actual award of 6,205 shares of common stock, which is in excess of the 6,104 shares previously reported on February 25, 2020.
F2 Represents shares of common stock withheld to pay taxes.